GALEAZZI, MAURO
 Distribuzione geografica
Continente #
NA - Nord America 27.963
EU - Europa 22.897
AS - Asia 3.374
SA - Sud America 33
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 27
AF - Africa 25
AN - Antartide 1
Totale 54.351
Nazione #
US - Stati Uniti d'America 27.905
GB - Regno Unito 9.051
IE - Irlanda 3.650
CN - Cina 3.013
UA - Ucraina 2.733
SE - Svezia 2.034
IT - Italia 1.567
DE - Germania 1.424
FR - Francia 1.326
FI - Finlandia 661
ES - Italia 104
RU - Federazione Russa 92
VN - Vietnam 92
BE - Belgio 78
TR - Turchia 77
IN - India 59
CA - Canada 46
NL - Olanda 30
PL - Polonia 28
AU - Australia 27
EU - Europa 25
CZ - Repubblica Ceca 21
KR - Corea 21
IR - Iran 20
GR - Grecia 15
CH - Svizzera 14
HK - Hong Kong 14
BR - Brasile 13
SG - Singapore 12
JP - Giappone 11
AT - Austria 10
BG - Bulgaria 9
DK - Danimarca 9
RO - Romania 8
ID - Indonesia 7
EG - Egitto 6
IL - Israele 6
MA - Marocco 6
SK - Slovacchia (Repubblica Slovacca) 6
ZA - Sudafrica 6
HU - Ungheria 5
KZ - Kazakistan 5
MY - Malesia 5
AL - Albania 4
AR - Argentina 4
BD - Bangladesh 4
CL - Cile 4
MX - Messico 4
NZ - Nuova Zelanda 4
PH - Filippine 4
SA - Arabia Saudita 4
CO - Colombia 3
CY - Cipro 3
DZ - Algeria 3
HR - Croazia 3
IM - Isola di Man 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
MK - Macedonia 3
PY - Paraguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CR - Costa Rica 2
CU - Cuba 2
EC - Ecuador 2
KE - Kenya 2
KW - Kuwait 2
PA - Panama 2
PE - Perù 2
PT - Portogallo 2
RS - Serbia 2
AM - Armenia 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GL - Groenlandia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
IQ - Iraq 1
JO - Giordania 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
NG - Nigeria 1
PK - Pakistan 1
SL - Sierra Leone 1
TW - Taiwan 1
Totale 54.351
Città #
Southend 8.589
Fairfield 3.997
Dublin 3.611
Menlo Park 2.428
Chandler 2.266
Jacksonville 2.232
Ashburn 2.208
Woodbridge 1.904
Houston 1.847
Wilmington 1.543
Seattle 1.479
Cambridge 1.342
Ann Arbor 1.163
Nanjing 757
Princeton 735
Beijing 658
Siena 527
Boardman 336
San Mateo 316
New York 285
Nanchang 249
San Diego 247
Helsinki 237
Dearborn 180
Shenyang 175
Düsseldorf 159
Hebei 127
Tianjin 121
Shanghai 119
Changsha 115
Venezia 107
Jiaxing 105
Málaga 96
Dong Ket 90
Kunming 88
Lancaster 86
Brussels 73
Jinan 73
Norwalk 66
Izmir 58
London 55
Washington 55
Rome 53
Saint Petersburg 53
Guangzhou 50
Mestre 50
Ningbo 48
Zhengzhou 48
San Francisco 47
Falls Church 44
Hangzhou 44
Redwood City 42
Milan 40
Changchun 39
Taizhou 35
Toronto 31
Lanzhou 25
Tappahannock 25
Hefei 24
Los Angeles 24
Florence 23
Fremont 23
Fuzhou 19
Kraków 18
Olomouc 18
Bologna 17
Hounslow 17
Frankfurt am Main 16
Kiev 16
Asciano 14
Paris 14
Chiswick 13
Chicago 12
Kilburn 12
Phoenix 12
Prescot 12
Amsterdam 11
Edinburgh 11
Philadelphia 11
Pisa 10
Singapore 10
Vienna 10
Auburn Hills 9
Central 9
Groningen 9
Hanover 9
Messina 9
Napoli 9
Bari 8
Haikou 8
Melbourne 8
São Paulo 8
Zanjan 8
Delhi 7
Nashville 7
New Bedfont 7
Padova 7
Pune 7
Sacramento 7
Sofia 7
Totale 42.088
Nome #
null 412
Comparison of combination therapies in the treatment of rheumatoid arthritis :leflunomide-anti-TNF-alfa versus methotrexate-anti-TNF-alfa 352
UNIREUMA -REUMATOLOGIA PER STUDENTI E MEDICI DI MEDICINA GENERALE I EDIZIONE 281
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study 248
Obesity reduces the response rate to anti TNFα in rheumatoidarthritis. an approach to a personalized medicine. 242
Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis 239
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry 231
Arrhythmogenicity of Anti-Ro/SSA antibodies in patients with torsades de pointes 226
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis 223
Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system 220
Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung 215
Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project" 211
Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. 209
The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF-α 203
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 200
Antiarrhythmic potential of anti-cytokine therapy in rheumatoid arthritis: Tocilizumab reduces QTc interval by controlling systemic inflammation. 198
One-year follow-up of mud-bath therapy in patients with bilateral knee osteoarthritis: a randomized, single-blind controlled trial 196
Eosinophilia-associated muscle disorders:an immunohistological study with tissue localisation of major basic protein in distinct clinicopathological forms 196
Validation of an Italian version of the functional index for hand osteoarthritis (FIHOA) 195
Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review 193
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies 192
Bone mineral density in patients with systemic sclerosis. 190
Ultrasonography and magnetic resonance imaging of heel fat pad inflammatory-oedematous lesions in rheumatoid arthritis 187
Weekly oral alendronate in mevalonate kinase deficiency 187
Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults 187
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 187
Change perspective to increase diagnostic accuracy of ultrasonography in calcium pyrophosphate dehydrate deposition disease! A new approach: The axial scan of the meniscus 186
The Immunogenetics of the Antiphospholipid Syndrome, Anticardiolipin Antibodies, and Lupus Anticoagulant 185
Expression of RXFP1 in skin of scleroderma patients and control subjects 184
Alkaptonuria is a novel human secondary amyloidogenic disease 183
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study 181
Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet’s Disease 180
Livello sierico della COMP (Cartilage Oligomeric Matrix Protein): Uso potenziale come marker di progressione del danno articolare nei pazienti con "Early Rheumatoid Arthritis" 179
SAT0312 Ultrasound Reliability in the Diagnosis of Calcium Pyrophosphate Deposition Disease: Agreement Between Observers and Main Causes of Discordance 177
FRI0501 Ultrasound versus synovial fluid analysis for the diagnosis of calcium pyrophosphate dihydrate deposition disease: preliminary results 177
High levels of maternal serum IL-17 and activin A in pregnant women affected by systemic lupus erythematosus 177
Colchicine myopathy and neuromyopathy: two cases with different characteristics 176
The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease 176
Deltoideal acromial enthesopathy in ankylosing spondylitis and in spondylarthropathies: comment on the article by Lambert et al. 175
SAT0564 Articular Involvement in Behçet Disease: An Ultrasonographic Study 173
Circulating levels of adiponectin, resistin, and visfatin after mud-bath therapy in patients with bilateral knee osteoarthritis 173
Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature 173
Increased serum leptin and visfatin levels in patients with diffuse idiopathic skeletal hyperostosis: a comparative study 171
The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy 171
Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus 170
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis 170
A "new" technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography 170
Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection 169
Anti-cofactor autoantibodies in systemic lupus erythematosus: prevalence, clinical and HLA class II associations 169
Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study 167
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab 166
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders 165
Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series 165
Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis 164
FRI0533 Ultrasonographic Features of Joints and Entheses in Healty Children 164
Working the endless puzzle of hereditary autoinflammatory disorders. 164
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 164
Anti-Ro/SSA-associated corrected QT interval prolongation in adults: the role of antibody level and specificity 163
Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis 163
Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema 163
AB1308 Prevalence of baker’s CYST in patients with chronic gonalgia and relationship with major non inflammatory diseases 162
High frequency of psoriasis in relatives is associated with early onset in an Italian multiple sclerosis cohort 162
Viral genotype and HLA class II alleles influence on extra-hepatic manifestations of chronic HCV infection 161
Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients 160
SAT0542 The Prevalence of Calcium Pyrophosphate Deposits at Ultrasound Examination: Retrospective Analysis in A Cohort of Patients 160
Absence of anti-cyclic citrullinated peptide antibodies in erosive osteoarthritis: further serological evidence of the disease as a subset of osteoarthritis 159
Sindrome di Churg-Strauss e gravidanza efficacia del trattamento con immunoglobuline endovena 159
SAT0315 Calcium Pyrophosphate Dihydrate Deposition Disease: A Proposal of New Ultrasonographic Criteria for CPP Identification in the Joints 158
Untangling the Web of Systemic Autoinflammatory Diseases 157
Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature 157
Connective tissue diseases and cardiac rhythm disorders: an overview 156
AB0535 Effects of tocilizumab on bone density and metabolism in patients with active rheumatoid arthritis 156
SAT0510 Ultrasound versus Synovial Fluid Analysis for the Diagnosis of Calcium Pyrophosphate Dihydrate Deposition Disease: is IT Cppd? Ask Us! 156
Statins and the joint: multiple targets for a global protection? 156
Granulomatosis with polyangiitis and intravenous immunoglobulins: A case series and review of the literature 155
Hydrostatic pressure regulates MicroRNA expression levels in osteoarthritic chondrocyte cultures via the Wnt/β-catenin pathway 155
Could oxidative stress regulate the expression of microRNA-146a and microRNA-34a in human osteoarthritic chondrocyte cultures? 155
SAT0530 The Useful of us in Diagnosis of Carpal Tunnel Syndrome in Diabetics: a Proposal for New Reference Values 154
Relationship between serum comp levels and serological markers of disease activity in rheumatoid arthritis patients treated with anti-tnf drugs. A study of the best way to manage indicators of response to therapy 154
AB0969 Accuracy of blind intra-articular injections in patients with osteoarthritis of the knee. An ultrasonography controlled study 154
Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease 154
Can hybrid hyaluronic acid represent a valid approach to treat rizoarthrosis? A retrospective comparative study 153
Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis 153
Autoinflammatory disorders and patients with isolated serosal involvement. 152
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683 152
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 152
A whitish-creamysynovial fluid. 151
Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome 151
null 150
Fasitibant prevents the bradykinin andinterleukin 1β synergism on prostaglandin E(2) release and cyclooxygenase 2expression in human fibroblast-like synoviocytes. 150
Efficacy and Safety of Adalimumab in Behçet’s disease related uveitis: a multicenter retrospective observational study 150
Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease: ultrasonographic criteria proposed. 149
Short- and long-term effects of spa therapy in knee osteoarthritis 148
IL-6 blockade in the management of non-infectious uveitis 148
Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy 148
Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? 147
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register 147
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study 147
Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments 147
Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA positive connective tissue diseases 146
Totale 17.814
Categoria #
all - tutte 150.609
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.609


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.488 0 0 0 0 0 0 0 0 0 0 0 1.488
2019/202012.423 1.504 557 905 1.937 740 986 955 1.566 966 1.124 448 735
2020/20217.859 397 940 195 776 357 1.120 274 1.245 734 588 634 599
2021/20226.301 532 768 428 492 430 157 258 244 441 737 589 1.225
2022/20238.055 536 580 1.079 1.191 874 1.659 108 630 838 164 256 140
2023/20244.977 232 130 441 299 188 1.554 1.761 142 24 61 71 74
Totale 54.914